These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Factors predictive of the development of levodopa-induced dyskinesia and Wearing-Off in Parkinson's disease. Rajput AH Mov Disord; 2014 Mar; 29(3):429. PubMed ID: 24375668 [No Abstract] [Full Text] [Related]
4. White matter connectivity networks predict levodopa-induced dyskinesia in Parkinson's disease. Jung JH; Kim YJ; Chung SJ; Yoo HS; Lee YH; Baik K; Jeong SH; Lee YG; Lee HS; Ye BS; Sohn YH; Jeong Y; Lee PH J Neurol; 2022 Jun; 269(6):2948-2960. PubMed ID: 34762146 [TBL] [Abstract][Full Text] [Related]
5. Amantadine's role in the treatment of levodopa-induced dyskinesia. Rodnitzky RL; Narayanan NS Neurology; 2014 Jan; 82(4):288-9. PubMed ID: 24371305 [No Abstract] [Full Text] [Related]
6. An Indirect Proof for Levodopa-Induced Vitamin Deficiency in Parkinson's Disease. Müller T; Kuhn W Mov Disord; 2023 Dec; 38(12):2319-2320. PubMed ID: 38113316 [No Abstract] [Full Text] [Related]
7. [Systemic review and meta-analysis of tolerability and safety between different titration regimes of ropinirol dose in the treatment of Parkinson's disease]. Chacon J Neurologia; 2007 Dec; 22(10):882-94. PubMed ID: 17602337 [TBL] [Abstract][Full Text] [Related]
8. Levodopa-induced dyskinesia: a brief review of the ongoing clinical trials. Huot P; Kang W; Kim E; Bédard D; Belliveau S; Frouni I; Kwan C Neurodegener Dis Manag; 2022 Apr; 12(2):51-55. PubMed ID: 34939425 [No Abstract] [Full Text] [Related]
9. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Inzelberg R; Schechtman E; Nisipeanu P Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891 [TBL] [Abstract][Full Text] [Related]